» Articles » PMID: 8226987

Microtubule-associated Protein Tau. Abnormal Phosphorylation of a Non-paired Helical Filament Pool in Alzheimer Disease

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 1993 Nov 15
PMID 8226987
Citations 283
Authors
Affiliations
Soon will be listed here.
Abstract

The major protein subunit of the paired helical filaments (PHF) of Alzheimer disease (AD) is the microtubule-associated protein tau. Tau is a family of phosphopolypeptides that are abnormally phosphorylated in PHF. In this study, a non-PHF pool of tau abnormally phosphorylated at Ser-199/202, and tau not phosphorylated at this site (AD P-tau and AD tau, respectively) were isolated from the 27,000 x g to 200,000 x g fraction of AD brain homogenate by extraction in 8 M urea, followed by dialysis against Tris buffer. AD P-tau and AD tau were further purified and separated from each other by acid precipitation, glial fibrillary acidic protein affinity chromatography, and phosphocellulose chromatography. The resulting AD P-tau and AD tau preparations were free of cytoskeletal proteins, ubiquitin, and beta-amyloid peptide. Immunochemical and morphological analysis of AD P-tau preparations revealed that most of the protein was of non-PHF origin. The AD P-tau was about 3-4-fold (approximately 8 mol P04/mol protein, M(r) 41,318) more phosphorylated than cytosolic tau from AD and control brains. Unlike PHF, the AD P-tau lacked ubiquitin. In AD brain the levels of cytosolic tau were about half of those in control aged cases. These findings suggest that the abnormal phosphorylation of tau in AD occurs in the cytosol.

Citing Articles

Phospho-tau serine-262 and serine-356 as biomarkers of pre-tangle soluble tau assemblies in Alzheimer's disease.

Islam T, Hill E, Abrahamson E, Servaes S, Smirnov D, Zeng X Nat Med. 2025; 31(2):574-588.

PMID: 39930142 PMC: 11835754. DOI: 10.1038/s41591-024-03400-0.


Natural products against tau hyperphosphorylation-induced aggregates: Potential therapies for Alzheimer's disease.

Basurto-Islas G, Diaz M, Ocampo L, Martinez-Herrera M, Lopez-Camacho P Arch Pharm (Weinheim). 2025; 358(1):e2400721.

PMID: 39888017 PMC: 11781347. DOI: 10.1002/ardp.202400721.


Comprehensive review on Alzheimer's disease: From the posttranslational modifications of Tau to corresponding treatments.

Li X, Ba Z, Huang J, Chen J, Jiang J, Huang N Ibrain. 2024; 10(4):427-438.

PMID: 39691421 PMC: 11649392. DOI: 10.1002/ibra.12176.


Post-Translational Modifications Control Phase Transitions of Tau.

Powell W, Nahum M, Pankratz K, Herlory M, Greenwood J, Poliyenko D ACS Cent Sci. 2024; 10(11):2145-2161.

PMID: 39634209 PMC: 11613296. DOI: 10.1021/acscentsci.4c01319.


Pathological Involvement of Protein Phase Separation and Aggregation in Neurodegenerative Diseases.

Wu Y, Ma B, Liu C, Li D, Sui G Int J Mol Sci. 2024; 25(18).

PMID: 39337671 PMC: 11432175. DOI: 10.3390/ijms251810187.